A validated panel of commercial antibodies for reliable detection of FET proteins.
Sara TacconelliiD, Laura Odemwingie, Stefan ReberiD, Sergio Di Pancrazio, Tatjana I. Zoller, Luca BiasettiiD, Claire TroakesiD, Marc‐David RueppiD, Caroline A. VanceiD
Abstract
The FET protein family comprises the highly conserved RNA-binding proteins FUS, EWS and TAF15 which are implicated in RNA metabolism and neurodegenerative diseases such as ALS and FTLD. Despite their structural similarity, reliable detection of individual FET proteins remains challenging due to antibody cross-reactivity and inconsistent localisation patterns reported in the literature. To address this, we systematically evaluated 23 commercially available antibodies for specificity and performance across western blotting, immunocytochemistry, and immunohistochemistry. Using single and double shRNA knockdowns in HeLa cells, we confirmed target engagement and identified antibodies which were specific as well as those with significant cross-reactivity. Immunofluorescence in rat primary neurons and HeLa cells showed antibody and cell type dependent variations in nuclear and cytoplasmic localisation; from these, we identified a subset that demonstrated high-quality, region-specific staining in postmortem human brain tissue. Our findings highlight substantial variability in antibody performance and underscore the need for rigorous validation to ensure reproducibility in FET protein research. We present a validated panel of antibodies suitable for diverse applications, providing a critical resource for studies of FET protein biology and pathology.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Computationally Designed RNA Aptamers Enable Selective Detection of FUS Pathology in ALS
Elsa Zacco, Martina Gilodi, … Gian Gaetano Tartaglia·bioRxiv·Apr 30, 2025
- Implementation of an antibody validation procedure: Application to the major ALS/FTD disease gene C9ORF72
Carl Laflamme, Paul M. McKeever, … Peter Scottt McPherson·eLifePeer-reviewed·Oct 14, 2019
- A validated antibody toolbox for ALS research
Riham Ayoubi, Emma J. MacDougall, … Carl Laflamme·bioRxiv·Sep 14, 2025
- Development of an enhanced anti-pan-N-formylmethionine-specific antibody
Dasom Kim, Kyu‐Sang Park, Cheol‐Sang Hwang·BioTechniquesPeer-reviewed·Feb 1, 2025
- Uman Type NF-L Antibodies Are Effective Reagents for the Imaging of Neurodegeneration
Gerry Shaw, Irina Madorsky, … David Dwight Fuller·bioRxiv·Aug 27, 2022
- FUS and TAF15 safeguard the critical functions of the ribonucleoprotein network formed by EWSR1 and newly synthesized RNA
Soumya Sundara Rajan, Imran Khan, … Natasha J. Caplen·bioRxiv·Mar 26, 2026